The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess the effect that Celebrex (a COX-2 inhibitor and non-steroidal anti-inflammatory drug) has on ovulation.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: Society of Family Planning
• Treatments: Celecoxib; Cyclooxygenase 2 Inhibitors

Criteria

Inclusion Criteria:

• Age 18-35

• Currently NOT using hormonal contraception

• Cycle length between 26-34 days

• General good health (specifically no hx of: diabetes, cardiac problems, moderate/severe heart burn (GERD), obesity (BMI > 30), hypertension (BP > 130/80)

• Willing and able to agree to randomization and informed consent

• Willing and able to use a menstrual diary to chart bleeding Serum progesterone > 3 ng/ml (from cycle day 18-25)

• Willing and able to return to clinic for bi-weekly for blood tests and ultrasounds throughout cycles 2, 3 & 5

Exclusion Criteria:

• Diabetes

• Cardiac disease

• Moderate to severe heart burn (or GERD) Obesity (BMI > 30) Hypertension (BP > 130/80)

• Allergy to NSAIDS

• Currently pregnant or trying to conceive

• Polycystic Ovarian Syndrome

• Use of hormonal contraception (participants can use barrier methods, spermicide, female or male sterilization, copper intrauterine device, abstinence, or have female partners